Cardiac Resynchronization Therapy Market By Device Type (Cardiac Resynchronization Therapy Defibrillator (CRT-D), Cardiac Resynchronization Therapy Pacemaker (CRT-P)); By Therapeutic Indication (Heart Failure (Moderate to Severe), Abnormal Heart Rhythm); By End Users (Hospitals & Clinics, Specialty Cardiac Centers, Ambulatory Surgical Centers); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Chronic disorders such as congestive heart failure, hypertension, and arrhythmia are becoming more common as the population ages. According to the American Heart Association's Heart & Stroke Statistics report from 2020, about 356,000 cases of out-of-hospital cardiac arrest (OHCA) occur in the United States each year, with around 90% of these being fatal. Cardiac resynchronization therapy (CRT) is a treatment that helps the heart beat in a more regular rhythm. It utilises a pacemaker to restore the heartbeat's regular timing rhythm. Over the forecast period, the global cardiac resynchronization therapy market is expected to be fuelled by new and innovative product introductions as well as increased acceptance of cardiac resynchronization therapy defibrillators. The rising demand for cardiac resynchronization therapy products is being driven by an increase in the incidence of target disease among the older population.
Furthermore, rising expenditure by various countries on improving their existing health care infrastructure, increase in disposable income among the middle class population, and rising middle class population around the world are some other factors positively influencing the global cardiac resynchronization therapy market's development trajectory. Furthermore, companies in the global cardiac resynchronization therapy market are working hard to gain regulatory approval for their new and innovative products. For instance, in 2017, the United States Food and Drug Administration (FDA) approved Medtronic's quadripolar cardiac resynchronization therapy peacemakers, which improve therapy delivery for heart failure patients. Moreover in 2017, they were also granted CE mark authorization for their quadripolar cardiac resynchronization treatment peacemaker products.
In terms of revenue, cardiac resynchronization therapy market was valued at US$ 4038.35 Mn in 2020 growing at a CAGR of 5.6% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Cardiac Resynchronization Therapy Market Revenue & Forecast, (US$ Million), 2015 – 2029
Device Type Outlook:
The device type segment in the global cardiac resynchronization therapy market is segmented into cardiac resynchronization therapy defibrillator (CRT-D) and cardiac resynchronization therapy pacemaker (CRT-P). Cardiac resynchronization therapy defibrillator (CRT-D) held the highest share in the market in 2020. A CRT-D is a specialised device for people with heart failure and a high risk of sudden cardiac death. While a CRT-D device treats sluggish cardiac beats like a regular pacemaker, it also sends modest electrical impulses to the left and right ventricles to help them contract at the same time. Cardiac resynchronization therapy device manufacturers are looking forward to incorporate advanced technologies for effective use of the devices. There have been significant recent breakthroughs in implantable cardioverter defibrillator (ICD) technology, including the introduction of quadripolar lead devices to increase device programming and therapeutic effectiveness, as well as improvements in patient monitoring to reduce unnecessary shocks. For instance, Abbott offers defibrillator Entrant HF CRT-D, with smartphone connectivity and long-lasting therapy, which can intuitively program to make a powerful difference in the patient’s heart failure. Thus, such technological advancements in the devices used for cardiac resynchronization therapy, showcases potential growth opportunities for global cardiac resynchronization therapy market over the period of next eight years.
By Therapeutic Indication
Based on type of therapeutic indication, the global cardiac resynchronization therapy market is bifurcated into heart failure (moderate to severe) and abnormal heart rhythm. Heart failure accounted for the highest share in the global cardiac resynchronization therapy market in the year 2020. Cardiovascular diseases (CVDs) are the world's leading cause of mortality, affecting an estimated 17.9 million people each year. Heart attacks and strokes are responsible for more than four out of every five CVD deaths, with one-third of these deaths occurring before the age of 70. In the recent years CRT (cardiac resynchronization therapy) has been adopted on a large scale as the treatment, which helps the heart beat in a more regular rhythm. It utilises a pacemaker to restore the heartbeat's regular timing rhythm. CRT has been found in recent studies to improve cardiac function in individuals with mild heart failure and lower the likelihood of heart failure hospitalisation.
End User Outlook:
Based on end user, the global cardiac resynchronization therapy market is segmented into hospitals & clinics, specialty cardiac centers, and ambulatory surgical centers. Hospitals & clinics as end users held the highest share in 2020. Cardiac resynchronization therapy (CRT) uses a device in which it provides electrical signals to both bottom chambers of the heart during cardiac resynchronization therapy (CRT). The therapy requires a minor surgical procedure to implant a pacemaker in the patient’s chest. As the procedure for implant is considered to be delicate and risky, cardiac resynchronization therapy has been found to improve heart failure-related hospitalizations, death, and a variety of quality-of-life indicators in meta-analyses and randomised clinical studies. Moreover healthcare organizations along with government initiatives are launching various schemes for cardiac resynchronization therapy to provide access and affordable treatments to the patients. Thus, owing to the above mentioned factors the global cardiac resynchronization therapy market is boosting globally.
Region Outlook:
North America dominated the global cardiac resynchronization therapy market in the year 2020. Chronic heart failure (CHF) is a major public health issue in the United States, affecting an estimated 4.9 million people and resulting in high hospitalisation rates, poor quality of life, and even deaths. The expansion of the cardiac resynchronization treatment market in the United States has been supported by an increase in the elderly population, an increase in the prevalence of cardiovascular disorders, and the development of healthcare infrastructure.
Competitive Landscape
The report provides both, qualitative and quantitative research of cardiac resynchronization therapy market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global cardiac resynchronization therapy market are:
- Abbott
- BIOTRONIK Asia Pacific Pte. Ltd.
- Boston Scientific Corporation
- MEDICO S.R.L.
- Medtronic
- MicroPort Scientific Corporation
- Other Market Participants.
Global Cardiac Resynchronization Therapy Market:
- By Device Type
- Cardiac Resynchronization Therapy Defibrillator (CRT-D)
- Cardiac Resynchronization Therapy Pacemaker (CRT-P)
- By Therapeutic Indication
- Heart Failure (Moderate to Severe)
- Abnormal Heart Rhythm
- By End Users
- Hospitals & Clinics
- Specialty Cardiac Centers
- Ambulatory Surgical Centers
- By Region
- North America
- S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2019
1.2.2. Base Year: 2020
1.2.3. Forecast Years: 2021 – 2029
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Cardiac Resynchronization Therapy Market
6.
Market
Synopsis: Cardiac Resynchronization
Therapy Market
7.
Cardiac
Resynchronization Therapy Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in Cardiac Resynchronization Therapy
Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Cardiac Resynchronization Therapy Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Cardiac
Resynchronization Therapy Market
8.
Global
Cardiac Resynchronization Therapy Market Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global Cardiac Resynchronization Therapy
Market Revenue (US$ Mn)
8.2. Global Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
8.2.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.1.3.
Market
Forecast, 2021 - 2029
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2020
8.2.1.5.1.2. Market Forecast, 2021 - 2029
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2020
8.2.1.5.2.2. Market Forecast, 2021 - 2029
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2020
8.2.1.5.3.2. Market Forecast, 2021 - 2029
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2020
8.2.1.5.4.2. Market Forecast, 2021 - 2029
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2020
8.2.1.5.5.2. Market Forecast, 2021 - 2029
8.2.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.2.3.
Market
Forecast, 2021 - 2029
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2020
8.2.2.5.1.2. Market Forecast, 2021 - 2029
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2020
8.2.2.5.2.2. Market Forecast, 2021 - 2029
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2020
8.2.2.5.3.2. Market Forecast, 2021 - 2029
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2020
8.2.2.5.4.2. Market Forecast, 2021 - 2029
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2020
8.2.2.5.5.2. Market Forecast, 2021 - 2029
8.3. Key Segment for Channeling Investments
8.3.1. By Device Type
9.
Global
Cardiac Resynchronization Therapy Market Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
9.2.1. Heart Failure (Moderate to Severe)
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.1.3.
Market
Forecast, 2021 - 2029
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North America
9.2.1.5.1.1. Market Estimation, 2015 - 2020
9.2.1.5.1.2. Market Forecast, 2021 - 2029
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2020
9.2.1.5.2.2. Market Forecast, 2021 - 2029
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2020
9.2.1.5.3.2. Market Forecast, 2021 - 2029
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2020
9.2.1.5.4.2. Market Forecast, 2021 - 2029
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2020
9.2.1.5.5.2. Market Forecast, 2021 - 2029
9.2.2. Abnormal Heart Rhythm
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.2.3.
Market
Forecast, 2021 - 2029
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2020
9.2.2.5.1.2. Market Forecast, 2021 - 2029
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2020
9.2.2.5.2.2. Market Forecast, 2021 - 2029
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2020
9.2.2.5.3.2. Market Forecast, 2021 - 2029
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2020
9.2.2.5.4.2. Market Forecast, 2021 - 2029
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2020
9.2.2.5.5.2. Market Forecast, 2021 - 2029
9.3. Key Segment for Channeling Investments
9.3.1. By Therapeutic Indication
10. Global Cardiac Resynchronization Therapy
Market Analysis and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
10.2.1. Hospitals and Clinics
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 -
2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2020
10.2.1.5.1.2. Market Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2020
10.2.1.5.2.2. Market Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2020
10.2.1.5.3.2. Market Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2020
10.2.1.5.4.2. Market Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2020
10.2.1.5.5.2. Market Forecast, 2021 - 2029
10.2.2. Specialty Cardiac Centers
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2020
10.2.2.5.1.2. Market Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2020
10.2.2.5.2.2. Market Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2020
10.2.2.5.3.2. Market Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2020
10.2.2.5.4.2. Market Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2020
10.2.2.5.5.2. Market Forecast, 2021 - 2029
10.2.3. Ambulatory Surgical Centers
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 -
2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2020
10.2.3.5.1.2. Market Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2020
10.2.3.5.2.2. Market Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2020
10.2.3.5.3.2. Market Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2020
10.2.3.5.4.2. Market Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2020
10.2.3.5.5.2. Market Forecast, 2021 - 2029
10.3. Key Segment for Channeling Investments
10.3.1. By End Users
11. North America Cardiac Resynchronization
Therapy Market Analysis and Forecasts, 2021 - 2029
11.1. Overview
11.1.1. North America Cardiac Resynchronization
Therapy Market Revenue (US$ Mn)
11.2. North America Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
11.2.1. Cardiac Resynchronization Therapy Defibrillator
(CRT-D)
11.2.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
11.3. North America Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
11.3.1. Heart Failure (Moderate to Severe)
11.3.2. Abnormal Heart Rhythm
11.4. North America Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
11.4.1. Hospitals and Clinics
11.4.2. Specialty Cardiac Centers
11.4.3. Ambulatory Surgical Centers
11.5. North America Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Cardiac Resynchronization Therapy Market
Revenue (US$ Mn) and Forecasts, By Device Type
11.5.1.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
11.5.1.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
11.5.1.2. U.S Cardiac Resynchronization Therapy Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
11.5.1.2.1. Heart Failure (Moderate to Severe)
11.5.1.2.2. Abnormal Heart Rhythm
11.5.1.3. U.S Cardiac Resynchronization Therapy Market
Revenue (US$ Mn) and Forecasts, By End Users
11.5.1.3.1. Hospitals and Clinics
11.5.1.3.2. Specialty Cardiac Centers
11.5.1.3.3. Ambulatory Surgical Centers
11.5.2. Canada
11.5.2.1. Canada Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
11.5.2.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
11.5.2.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
11.5.2.2. Canada Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
11.5.2.2.1. Heart Failure (Moderate to Severe)
11.5.2.2.2. Abnormal Heart Rhythm
11.5.2.3. Canada Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
11.5.2.3.1. Hospitals and Clinics
11.5.2.3.2. Specialty Cardiac Centers
11.5.2.3.3. Ambulatory Surgical Centers
11.5.3. Mexico
11.5.3.1. Mexico Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
11.5.3.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
11.5.3.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
11.5.3.2. Mexico Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
11.5.3.2.1. Heart Failure (Moderate to Severe)
11.5.3.2.2. Abnormal Heart Rhythm
11.5.3.3. Mexico Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
11.5.3.3.1. Hospitals and Clinics
11.5.3.3.2. Specialty Cardiac Centers
11.5.3.3.3. Ambulatory Surgical Centers
11.5.4. Rest of North America
11.5.4.1. Rest of North America Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
11.5.4.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
11.5.4.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
11.5.4.2. Rest of North America Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Indication
11.5.4.2.1. Heart Failure (Moderate to Severe)
11.5.4.2.2. Abnormal Heart Rhythm
11.5.4.3. Rest of North America Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
11.5.4.3.1. Hospitals and Clinics
11.5.4.3.2. Specialty Cardiac Centers
11.5.4.3.3. Ambulatory Surgical Centers
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Device Type
11.6.3. By Therapeutic Indication
11.6.4. By End Users
12. Europe Cardiac Resynchronization Therapy
Market Analysis and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. Europe Cardiac Resynchronization Therapy
Market Revenue (US$ Mn)
12.2. Europe Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
12.2.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
12.2.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
12.3. Europe Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.3.1. Heart Failure (Moderate to Severe)
12.3.2. Abnormal Heart Rhythm
12.4. Europe Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
12.4.1. Hospitals and Clinics
12.4.2. Specialty Cardiac Centers
12.4.3. Ambulatory Surgical Centers
12.5. Europe Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
12.5.1.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
12.5.1.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
12.5.1.2. France Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.1.2.1. Heart Failure (Moderate to Severe)
12.5.1.2.2. Abnormal Heart Rhythm
12.5.1.3. France Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.1.3.1. Hospitals and Clinics
12.5.1.3.2. Specialty Cardiac Centers
12.5.1.3.3. Ambulatory Surgical Centers
12.5.2. The UK
12.5.2.1. The UK Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
12.5.2.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
12.5.2.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
12.5.2.2. The UK Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.2.2.1. Heart Failure (Moderate to Severe)
12.5.2.2.2. Abnormal Heart Rhythm
12.5.2.3. The UK Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.2.3.1. Hospitals and Clinics
12.5.2.3.2. Specialty Cardiac Centers
12.5.2.3.3. Ambulatory Surgical Centers
12.5.3. Spain
12.5.3.1. Spain Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
12.5.3.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
12.5.3.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
12.5.3.2. Spain Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.3.2.1. Heart Failure (Moderate to Severe)
12.5.3.2.2. Abnormal Heart Rhythm
12.5.3.3. Spain Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.3.3.1. Hospitals and Clinics
12.5.3.3.2. Specialty Cardiac Centers
12.5.3.3.3. Ambulatory Surgical Centers
12.5.4. Germany
12.5.4.1. Germany Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
12.5.4.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
12.5.4.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
12.5.4.2. Germany Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.4.2.1. Heart Failure (Moderate to Severe)
12.5.4.2.2. Abnormal Heart Rhythm
12.5.4.3. Germany Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.4.3.1. Hospitals and Clinics
12.5.4.3.2. Specialty Cardiac Centers
12.5.4.3.3. Ambulatory Surgical Centers
12.5.5. Italy
12.5.5.1. Italy Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
12.5.5.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
12.5.5.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
12.5.5.2. Italy Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.5.2.1. Heart Failure (Moderate to Severe)
12.5.5.2.2. Abnormal Heart Rhythm
12.5.5.3. Italy Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.5.3.1. Hospitals and Clinics
12.5.5.3.2. Specialty Cardiac Centers
12.5.5.3.3. Ambulatory Surgical Centers
12.5.6. Nordic Countries
12.5.6.1. Nordic Countries Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
12.5.6.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
12.5.6.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
12.5.6.2. Nordic Countries Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.6.2.1. Heart Failure (Moderate to Severe)
12.5.6.2.2. Abnormal Heart Rhythm
12.5.6.3. Nordic Countries Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.6.3.1. Hospitals and Clinics
12.5.6.3.2. Specialty Cardiac Centers
12.5.6.3.3. Ambulatory Surgical Centers
12.5.6.4. Nordic Countries Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux Union
12.5.7.1. Benelux Union Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
12.5.7.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
12.5.7.1.2. Cardiac Resynchronization Therapy Pacemaker (CRT-P)
12.5.7.2. Benelux Union Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.7.2.1. Heart Failure (Moderate to Severe)
12.5.7.2.2. Abnormal Heart Rhythm
12.5.7.3. Benelux Union Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.7.3.1. Hospitals and Clinics
12.5.7.3.2. Specialty Cardiac Centers
12.5.7.3.3. Ambulatory Surgical Centers
12.5.7.4. Benelux Union Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of Europe
12.5.8.1. Rest of Europe Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
12.5.8.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
12.5.8.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
12.5.8.2. Rest of Europe Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.8.2.1. Heart Failure (Moderate to Severe)
12.5.8.2.2. Abnormal Heart Rhythm
12.5.8.3. Rest of Europe Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.8.3.1. Hospitals and Clinics
12.5.8.3.2. Specialty Cardiac Centers
12.5.8.3.3. Ambulatory Surgical Centers
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Device Type
12.6.3. By Therapeutic Indication
12.6.4. By End Users
13. Asia Pacific Cardiac Resynchronization
Therapy Market Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Asia Pacific Cardiac Resynchronization
Therapy Market Revenue (US$ Mn)
13.2. Asia Pacific Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
13.2.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
13.2.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
13.3. Asia Pacific Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.3.1. Heart Failure (Moderate to Severe)
13.3.2. Abnormal Heart Rhythm
13.4. Asia Pacific Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
13.4.1. Hospitals and Clinics
13.4.2. Specialty Cardiac Centers
13.4.3. Ambulatory Surgical Centers
13.5. Asia Pacific Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
13.5.1.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
13.5.1.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
13.5.1.2. China Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.1.2.1. Heart Failure (Moderate to Severe)
13.5.1.2.2. Abnormal Heart Rhythm
13.5.1.3. China Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.1.3.1. Hospitals and Clinics
13.5.1.3.2. Specialty Cardiac Centers
13.5.1.3.3. Ambulatory Surgical Centers
13.5.2. Japan
13.5.2.1. Japan Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
13.5.2.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
13.5.2.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
13.5.2.2. Japan Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.2.2.1. Heart Failure (Moderate to Severe)
13.5.2.2.2. Abnormal Heart Rhythm
13.5.2.3. Japan Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.2.3.1. Hospitals and Clinics
13.5.2.3.2. Specialty Cardiac Centers
13.5.2.3.3. Ambulatory Surgical Centers
13.5.3. India
13.5.3.1. India Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
13.5.3.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
13.5.3.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
13.5.3.2. India Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.3.2.1. Heart Failure (Moderate to Severe)
13.5.3.2.2. Abnormal Heart Rhythm
13.5.3.3. India Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.3.3.1. Hospitals and Clinics
13.5.3.3.2. Specialty Cardiac Centers
13.5.3.3.3. Ambulatory Surgical Centers
13.5.4. New Zealand
13.5.4.1. New Zealand Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
13.5.4.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
13.5.4.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
13.5.4.2. New Zealand Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.4.2.1. Heart Failure (Moderate to Severe)
13.5.4.2.2. Abnormal Heart Rhythm
13.5.4.3. New Zealand Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.4.3.1. Hospitals and Clinics
13.5.4.3.2. Specialty Cardiac Centers
13.5.4.3.3. Ambulatory Surgical Centers
13.5.5. Australia
13.5.5.1. Australia Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
13.5.5.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
13.5.5.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
13.5.5.2. Australia Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.5.2.1. Heart Failure (Moderate to Severe)
13.5.5.2.2. Abnormal Heart Rhythm
13.5.5.3. Australia Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.5.3.1. Hospitals and Clinics
13.5.5.3.2. Specialty Cardiac Centers
13.5.5.3.3. Ambulatory Surgical Centers
13.5.6. South Korea
13.5.6.1. South Korea Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
13.5.6.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
13.5.6.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
13.5.6.2. South Korea Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.6.2.1. Heart Failure (Moderate to Severe)
13.5.6.2.2. Abnormal Heart Rhythm
13.5.6.3. South Korea Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.6.3.1. Hospitals and Clinics
13.5.6.3.2. Specialty Cardiac Centers
13.5.6.3.3. Ambulatory Surgical Centers
13.5.7. Southeast Asia
13.5.7.1. Southeast Asia Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
13.5.7.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
13.5.7.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
13.5.7.2. Southeast Asia Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.7.2.1. Heart Failure (Moderate to Severe)
13.5.7.2.2. Abnormal Heart Rhythm
13.5.7.3. Southeast Asia Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.7.3.1. Hospitals and Clinics
13.5.7.3.2. Specialty Cardiac Centers
13.5.7.3.3. Ambulatory Surgical Centers
13.5.7.4. Southeast Asia Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1. Rest of Asia Pacific Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
13.5.8.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
13.5.8.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
13.5.8.2. Rest of Asia Pacific Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.8.2.1. Heart Failure (Moderate to Severe)
13.5.8.2.2. Abnormal Heart Rhythm
13.5.8.3. Rest of Asia Pacific Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.8.3.1. Hospitals and Clinics
13.5.8.3.2. Specialty Cardiac Centers
13.5.8.3.3. Ambulatory Surgical Centers
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Device Type
13.6.3. By Therapeutic Indication
13.6.4. By End Users
14. Middle East and Africa Cardiac
Resynchronization Therapy Market Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Middle East and Africa Cardiac
Resynchronization Therapy Market Revenue (US$ Mn)
14.2. Middle East and Africa Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
14.2.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
14.2.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
14.3. Middle East and Africa Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Indication
14.3.1. Heart Failure (Moderate to Severe)
14.3.2. Abnormal Heart Rhythm
14.4. Middle East and Africa Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.4.1. Hospitals and Clinics
14.4.2. Specialty Cardiac Centers
14.4.3. Ambulatory Surgical Centers
14.5. Middle East and Africa Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1. Saudi Arabia Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
14.5.1.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
14.5.1.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
14.5.1.2. Saudi Arabia Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.5.1.2.1. Heart Failure (Moderate to Severe)
14.5.1.2.2. Abnormal Heart Rhythm
14.5.1.3. Saudi Arabia Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.1.3.1. Hospitals and Clinics
14.5.1.3.2. Specialty Cardiac Centers
14.5.1.3.3. Ambulatory Surgical Centers
14.5.2. UAE
14.5.2.1. UAE Cardiac Resynchronization Therapy Market
Revenue (US$ Mn) and Forecasts, By Device Type
14.5.2.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
14.5.2.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
14.5.2.2. UAE Cardiac Resynchronization Therapy Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.5.2.2.1. Heart Failure (Moderate to Severe)
14.5.2.2.2. Abnormal Heart Rhythm
14.5.2.3. UAE Cardiac Resynchronization Therapy Market
Revenue (US$ Mn) and Forecasts, By End Users
14.5.2.3.1. Hospitals and Clinics
14.5.2.3.2. Specialty Cardiac Centers
14.5.2.3.3. Ambulatory Surgical Centers
14.5.3. Egypt
14.5.3.1. Egypt Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
14.5.3.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
14.5.3.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
14.5.3.2. Egypt Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.5.3.2.1. Heart Failure (Moderate to Severe)
14.5.3.2.2. Abnormal Heart Rhythm
14.5.3.3. Egypt Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.3.3.1. Hospitals and Clinics
14.5.3.3.2. Specialty Cardiac Centers
14.5.3.3.3. Ambulatory Surgical Centers
14.5.4. Kuwait
14.5.4.1. Kuwait Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
14.5.4.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
14.5.4.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
14.5.4.2. Kuwait Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.5.4.2.1. Heart Failure (Moderate to Severe)
14.5.4.2.2. Abnormal Heart Rhythm
14.5.4.3. Kuwait Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.4.3.1. Hospitals and Clinics
14.5.4.3.2. Specialty Cardiac Centers
14.5.4.3.3. Ambulatory Surgical Centers
14.5.5. South Africa
14.5.5.1. South Africa Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
14.5.5.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
14.5.5.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
14.5.5.2. South Africa Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.5.5.2.1. Heart Failure (Moderate to Severe)
14.5.5.2.2. Abnormal Heart Rhythm
14.5.5.3. South Africa Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.5.3.1. Hospitals and Clinics
14.5.5.3.2. Specialty Cardiac Centers
14.5.5.3.3. Ambulatory Surgical Centers
14.5.6. Rest of Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
14.5.6.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
14.5.6.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
14.5.6.2. Rest of Middle East & Africa Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Indication
14.5.6.2.1. Heart Failure (Moderate to Severe)
14.5.6.2.2. Abnormal Heart Rhythm
14.5.6.3. Rest of Middle East & Africa Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.6.3.1. Hospitals and Clinics
14.5.6.3.2. Specialty Cardiac Centers
14.5.6.3.3. Ambulatory Surgical Centers
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Device Type
14.6.3. By Therapeutic Indication
14.6.4. By End Users
15. Latin America Cardiac Resynchronization Therapy
Market Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Latin America Cardiac Resynchronization
Therapy Market Revenue (US$ Mn)
15.2. Latin America Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
15.2.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
15.2.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
15.3. Latin America Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
15.3.1. Heart Failure (Moderate to Severe)
15.3.2. Abnormal Heart Rhythm
15.4. Latin America Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.4.1. Hospitals and Clinics
15.4.2. Specialty Cardiac Centers
15.4.3. Ambulatory Surgical Centers
15.5. Latin America Cardiac Resynchronization
Therapy Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
15.5.1.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
15.5.1.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
15.5.1.2. Brazil Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
15.5.1.2.1. Heart Failure (Moderate to Severe)
15.5.1.2.2. Abnormal Heart Rhythm
15.5.1.3. Brazil Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
15.5.1.3.1. Hospitals and Clinics
15.5.1.3.2. Specialty Cardiac Centers
15.5.1.3.3. Ambulatory Surgical Centers
15.5.2. Argentina
15.5.2.1. Argentina Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Device Type
15.5.2.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
15.5.2.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
15.5.2.2. Argentina Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
15.5.2.2.1. Heart Failure (Moderate to Severe)
15.5.2.2.2. Abnormal Heart Rhythm
15.5.2.3. Argentina Cardiac Resynchronization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Users
15.5.2.3.1. Hospitals and Clinics
15.5.2.3.2. Specialty Cardiac Centers
15.5.2.3.3. Ambulatory Surgical Centers
15.5.3. Rest of Latin America
15.5.3.1. Rest of Latin America Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By Device Type
15.5.3.1.1. Cardiac Resynchronization Therapy
Defibrillator (CRT-D)
15.5.3.1.2. Cardiac Resynchronization Therapy Pacemaker
(CRT-P)
15.5.3.2. Rest of Latin America Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Indication
15.5.3.2.1. Heart Failure (Moderate to Severe)
15.5.3.2.2. Abnormal Heart Rhythm
15.5.3.3. Rest of Latin America Cardiac
Resynchronization Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.5.3.3.1. Hospitals and Clinics
15.5.3.3.2. Specialty Cardiac Centers
15.5.3.3.3. Ambulatory Surgical Centers
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Device Type
15.6.3. By Therapeutic Indication
15.6.4. By End Users
16. Competitive Benchmarking
16.1. Market Share Analysis, 2020
16.2. Global Presence and Growth Strategies
16.2.1. Mergers and Acquisitions
16.2.2. Product Launches
16.2.3. Investments Trends
16.2.4. R&D Initiatives
17. Player Profiles
17.1. Abbott
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. BIOTRONIK Asia Pacific Pte. Ltd.
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. Boston Scientific Corporation
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. MEDICO S.R.L.
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. Medtronic
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. MicroPort Scientific Corporation.
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. Other Market Participants
18. Key Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.